Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Multiplex biomarker approach to cardiovascular diseases

M. Adamcova, F. Šimko,

. 2018 ; 39 (7) : 1068-1072. [pub] 20180412

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000808
E-zdroje Online Plný text

NLK Free Medical Journals od 1980
PubMed Central od 2009 do Před 1 rokem
Europe PubMed Central od 2009 do Před 1 rokem
ProQuest Central od 2005-01-01 do Před 1 rokem
Open Access Digital Library od 2009-01-01
Health & Medicine (ProQuest) od 2005-01-01 do Před 1 rokem

Personalized medicine is partly based on biomarker-guided diagnostics, therapy and prognosis, which is becoming an unavoidable concept in modern cardiology. However, the clinical significance of single biomarker studies is rather limited. A promising novel approach involves combining multiple markers into a multiplex panel, which could refine the management of a particular patient with cardiovascular pathology. Two principally different assay formats have been developed to facilitate simultaneous quantification of multiple antigens: planar array assays and microbead assays. These approaches may help to better evaluate the complexity and dynamic nature of pathologic processes and offer substantial cost and sample savings compared with traditional enzyme-linked immunosorbent assay (ELISA) measurements. However, a multiplex multimarker approach cannot become a generally disseminated method until analytical problems are solved and further studies confirming improved clinical outcomes are accomplished. These drawbacks underlie the fact that a limited number of systematic studies are available regarding the use of a multiplex biomarker approach in cardiovascular medicine to date. Our perspective underscores the significant potential of the use of the multiplex approach in a wider conceptual framework under the close cooperation of clinical and experimental cardiologists, pathophysiologists and biochemists so that the personalized approach based on standardized multimarker testing may improve the management of various cardiovascular pathologies and become a ubiquitous partner of population-derived evidence-based medicine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000808
003      
CZ-PrNML
005      
20190111144817.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/aps.2018.29 $2 doi
035    __
$a (PubMed)29645001
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Adamcova, Michaela $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic. adamcova@lfhk.cuni.cz.
245    10
$a Multiplex biomarker approach to cardiovascular diseases / $c M. Adamcova, F. Šimko,
520    9_
$a Personalized medicine is partly based on biomarker-guided diagnostics, therapy and prognosis, which is becoming an unavoidable concept in modern cardiology. However, the clinical significance of single biomarker studies is rather limited. A promising novel approach involves combining multiple markers into a multiplex panel, which could refine the management of a particular patient with cardiovascular pathology. Two principally different assay formats have been developed to facilitate simultaneous quantification of multiple antigens: planar array assays and microbead assays. These approaches may help to better evaluate the complexity and dynamic nature of pathologic processes and offer substantial cost and sample savings compared with traditional enzyme-linked immunosorbent assay (ELISA) measurements. However, a multiplex multimarker approach cannot become a generally disseminated method until analytical problems are solved and further studies confirming improved clinical outcomes are accomplished. These drawbacks underlie the fact that a limited number of systematic studies are available regarding the use of a multiplex biomarker approach in cardiovascular medicine to date. Our perspective underscores the significant potential of the use of the multiplex approach in a wider conceptual framework under the close cooperation of clinical and experimental cardiologists, pathophysiologists and biochemists so that the personalized approach based on standardized multimarker testing may improve the management of various cardiovascular pathologies and become a ubiquitous partner of population-derived evidence-based medicine.
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a kardiovaskulární nemoci $x diagnóza $x farmakoterapie $7 D002318
650    _2
$a ELISA $7 D004797
650    _2
$a lidé $7 D006801
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Šimko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. Third Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic.
773    0_
$w MED00193644 $t Acta pharmacologica Sinica $x 1745-7254 $g Roč. 39, č. 7 (2018), s. 1068-1072
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29645001 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190111145022 $b ABA008
999    __
$a ok $b bmc $g 1363928 $s 1038931
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 39 $c 7 $d 1068-1072 $e 20180412 $i 1745-7254 $m Acta pharmacologica Sinica $n Acta Pharmacol Sin $x MED00193644
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...